Last reviewed · How we verify
Chantix (varenicline)
Chantix works by activating the brain's nicotinic receptors, reducing cravings and the pleasurable effects of smoking.
Chantix (varenicline) is a small molecule cholinergic receptor agonist developed by Pfizer Inc, now owned by Pf Prism Cv. It targets the neuronal acetylcholine receptor alpha4/beta2, modulating the brain's reward system to aid smoking cessation. Approved by the FDA in 2006, Chantix is off-patent and has multiple generic manufacturers. As a cholinergic receptor agonist, it works by activating the brain's nicotinic receptors, reducing cravings and the pleasurable effects of smoking. Key safety considerations include neuropsychiatric events and cardiovascular risks.
At a glance
| Generic name | varenicline |
|---|---|
| Sponsor | Pfizer |
| Drug class | Cholinergic Receptor Agonist |
| Target | Neuronal acetylcholine receptor; alpha4/beta2 |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2006 |
Mechanism of action
Varenicline binds with high affinity and selectivity at 42 neuronal nicotinic acetylcholine receptors. The efficacy of varenicline tablets in smoking cessation is believed to be the result of vareniclines activity at 42 sub-type of the nicotinic receptor where its binding produces agonist activity, while simultaneously preventing nicotine binding to these receptors.Electrophysiology studies in vitro and neurochemical studies in vivo have shown that varenicline binds to 42 neuronal nicotinic acetylcholine receptors and stimulates receptor-mediated activity, but at significantly lower level than nicotine. Varenicline blocks the ability of nicotine to activate 42 receptors and thus to stimulate the central nervous mesolimbic dopamine system, believed to be the neuronal mechanism underlying reinforcement and reward experienced upon smoking. Varenicline is highly selective and binds more potently to 42 receptors than to other common nicotinic receptors (>500-fold 3
Approved indications
- Smoking cessation assistance
Common side effects
- Allergic reaction
- Serious skin reactions
- Mental Health Problems
- Heart attack
- Stroke
- Seizures
- Sleepwalking
- Nausea
- Vomiting
- Trouble sleeping
- Headache
- Abnormal dreams
Drug interactions
- bupropion
- nicotine replacement therapy (NRT)
- theophylline
- warfarin
- insulin
Key clinical trials
- Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2 (PHASE2)
- A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation (PHASE2,PHASE3)
- Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder (EARLY_PHASE1)
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse (NA)
- Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation (PHASE4)
- Preoperative Smoking Cessation in Patients Undergoing Surgery (NA)
- Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chantix CI brief — competitive landscape report
- Chantix updates RSS · CI watch RSS
- Pfizer portfolio CI